Will policy reversals for US federal staff speed up or slow down FDA efficiency?

US Health and Human Services (HHS) decision-makers have been shuttling personnel between employment and dismissal, much like the Grand Old Duke of York from the old English nursery rhyme marches troops up and down a hill.

News broke last week that an unclear number of employees at agencies across the HHS were going to be fired as part of a broader targeting of civil service numbers throughout numerous government departments, in line with an electoral promise by president Donald Trump. For the HHS, this included agencies such as the FDA as well as other entities that touch upon vaping and other nicotine alternative products – such as the Centers for Disease Control (CDC) and National Institutes of Health (NIH).

Read full article
I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the TobaccoIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation